Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 138 of 440 for:    hepatitis b | Open Studies

Tenofovir to Prevent HBV Reactivation

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2014 by University Health Network, Toronto
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: July 7, 2014
Last updated: NA
Last verified: June 2014
History: No changes posted

The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.

Condition Intervention Phase
Hepatitis B
Drug: Tenofovir disoproxil
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre Phase III Study to Evaluate Preemptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Rituximab-based Chemotherapy for Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Rate of reverse seroconversion [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
    The difference in the rate of reverse seroconversion or Hepatitis B (HBV)-associated hepatitis (definition: appearance of HBsAg in the serum with or without detectable HBV DNA in a patient who was previously HBsAg-/cAb+.) between the intervention and placebo groups.

Secondary Outcome Measures:
  • Rates of HBV Reactivation [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
  • Severe HBV-associated hepatitis [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
  • HBV-related liver failure [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
  • Liver-related death [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
  • Treatment-related adverse effects (AEs) [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]
  • Time to start chemotherapy [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: No ]
  • Chemotherapy interruption [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: No ]
  • All-cause mortality [ Time Frame: 12 months post-chemotherapy ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 184
Study Start Date: July 2014
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pre-emptive tenofovir
Tenofovir disoproxil
Drug: Tenofovir disoproxil
Other Name: Viread
Placebo Comparator: Placebo


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 years of age
  • Diagnosis of non-Hodgkin's lymphoma to be treated with rituximab-based chemotherapy
  • HBsAg negative, anti-HBc (core) positive

Exclusion Criteria:

  • Current therapy with known activity against HBV
  • Life expectancy < 3 months
  • HBsAg positive
  • Hepatitis D/Hepatitis C (HDV/HCV) or HIV co-infection
  • Creatinine clearance <50 mL/min
  • Intolerance to tenofovir
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02186574

Contact: Jordan Feld, MD 416-603-5914 ext 2684
Contact: Victor Lo, MASc, CCRP 416-603-5839

Canada, Ontario
Toronto Western Hospital Not yet recruiting
Toronto, Ontario, Canada, M5T 2S8
Contact: Victor Lo, MASc, CCRP    416-603-5839   
Contact: Seham Noureldin, PhD    416-603-5914 ext 2523   
Sub-Investigator: Harry Janssen, MD         
Sub-Investigator: David Wong, MD         
Sub-Investigator: Hemant Shah, MD         
Sub-Investigator: Joshua Juan, MD         
Sponsors and Collaborators
University Health Network, Toronto
Study Director: Harry Janssen, MD University Health Network, Toronto
  More Information

Additional Information:
No publications provided

Responsible Party: University Health Network, Toronto Identifier: NCT02186574     History of Changes
Other Study ID Numbers: JF62014
Study First Received: July 7, 2014
Last Updated: July 7, 2014
Health Authority: Canada: Health Canada

Keywords provided by University Health Network, Toronto:
Hepatitis B

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Hepatitis, Viral, Human
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Immune System Diseases
Immunoproliferative Disorders
Liver Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Tenofovir disoproxil
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors processed this record on November 25, 2014